Kardashian may be famous for her selfies, but the Food and Drug Administration was not a fan of her latest one
An
Instagram picture featuring Kardashian, morning sickness drug Diclegis and
accompanying text promoting the drug's benefits garnered more than 500,000
"likes" but brought about a formal FDA warning letter for the drug's
manufacturer.
Part
of the letter says, "The social media post is misleading because it
presents various efficacy claims for Diclegis, but fails to communicate any
risk information."
The
posts promoting the drug have since been taken down, but Kardashian, who was
paid to promote the drug, originally claimed it made her feel "a lot
better and most importantly, it's been studied and there was no increased risk
to the baby."Duchesnay, the pharmaceutical company behind the drug, told
CNBC that while Kim was paid to promote her experience with the drug she had
found it on her own accord through her family OB-GYN. The company said it would
take quick action in responding to the FDA's letter.
"Duchesnay
USA takes its regulatory responsibilities very seriously, and acknowledges that
its communications, including in social media as in this particular instance,
need to be in accordance with applicable rules and regulations," the
company said.The FDA warning letter also requests Duchesnay offer corrections
to the claims "using the same media" for the same audience. That
could mean a revised selfie for Kim's 42 million followers.
No comments:
Post a Comment